What You Should Know
- In a large study presented at a major cancer conference in October, an experimental drug called sonesitatug vedotin (Sone-Ve) helped people with advanced stomach cancer live longer, especially if their cancer kept growing after at least two earlier treatments.
- In that group, half the people on Sone-Ve were still alive at about 10 months. On standard treatment, that point came at about 5 months.
- Sone-Ve targets only tumors that carry a protein called claudin 18.2. A test on your tumor tissue shows whether yours does.
- Common side effects included nausea, vomiting and decreased appetite.
- The drug isn’t FDA approved yet; for now, it’s available only through clinical trials.
“These are very encouraging results for patients with advanced gastric and gastroesophageal cancer,” Dr. Yelena Janjigian, a Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center, tells SurvivorNet. “We have made tremendous progress in first-line treatment, but once those therapies stop working, our options are still quite limited.”
How Sone-Ve Works
Read MoreAbout Claudin 18.2
Claudin 18.2, or CLDN18.2, is a protein found on the surface of some stomach cancer cells. Drugs such as Sone-Ve can be designed to target it and attack cells that express it.
Your doctor finds out whether your cancer has this protein by testing a sample of your tumor in a lab. This biomarker test looks for a feature of your tumor that can guide treatment. If you have advanced stomach cancer, ask whether you’ve been tested. The result can open doors to treatments you might not otherwise be offered.
One approved drug already targets this protein. It’s called zolbetuximab (brand name Vyloy), and it’s given with chemotherapy as a first treatment.
What the Study Tested
The trial, called CLARITY-Gastric01, was a phase 3 study. That’s the large, late-stage kind of trial usually needed before a drug can be approved.
The 532 people in the main comparison had stomach cancer, or cancer where the esophagus meets the stomach. Their cancer had spread or couldn’t be removed with surgery, and it had kept growing after at least one earlier treatment. They were randomized, meaning assigned by chance, to get either Sone-Ve or a standard treatment chosen by their doctor, such as the chemo drugs paclitaxel, docetaxel or irinotecan.
To qualify, people needed at least 25% of their tumor cells to show claudin 18.2. That’s a lower bar than the one used for zolbetuximab, so more people may qualify.
What the Researchers Found
The clearest result came in people who’d already been through at least two treatments.
In that group, median overall survival was 10 months with Sone-Ve, compared with 5 months on standard treatment. Overall survival is how long people lived. The median is the point at which half the people in a group are still alive, and some people live well beyond it.
“What is particularly exciting about sonesitatug vedotin is that we are seeing a meaningful survival benefit even in patients whose cancer has progressed after multiple prior treatments,” Dr. Janjigian says.
She’s seen it in her own practice. “I have been treating patients with sonesitatug vedotin for several years. I have seen firsthand that this drug can help patients whose cancers have progressed despite prior chemotherapy,” she says.
She goes further: “I absolutely think these results are practice changing.”
The results across everyone in the study were more mixed. People on Sone-Ve lived longer overall: 10.6 months compared with 6.4 months. But the study had a second main goal, progression-free survival, which means how long people lived without their cancer growing. On that measure, Sone-Ve didn’t do clearly better than standard treatment.
The survival benefit held up whether a tumor had a moderate amount of claudin 18.2 or a lot of it.
What About People on Their Second Treatment?
This is where the picture is less clear. When researchers looked only at people getting Sone-Ve as their second treatment, they didn’t find a clear survival advantage.
Dr. Janjigian still sees a reason to want the drug available earlier. “Many of our patients deteriorate quickly once their initial treatment stops working. By the time they reach third-line therapy, some are simply too weak to receive additional treatment,” she explains. “We don’t want to miss the opportunity to offer patients an effective therapy while they are still well enough to benefit from it.”
Not every expert reads the data the same way. In comments published by ESMO, Prof. Salah-Eddin Al-Batran of the University Cancer Center Frankfurt in Germany said, “The situation in the second-line setting is less certain given the lack of a significant difference in PFS [progression-free survival], but the safety profile is manageable.”
What About Side Effects?
Because Sone-Ve targets claudin 18.2, it can upset your digestive system.
“We see gastrointestinal side effects, particularly nausea, vomiting, and decreased appetite,” Dr. Janjigian says. “These are especially important in gastric cancer patients, many of whom already struggle with nutrition and weight loss.”
The chemo part of the drug can also lower blood counts. It can cause peripheral neuropathy, which is nerve damage that can bring numbness, tingling or pain in your hands and feet.
“In my experience, these side effects are generally manageable with supportive care and dose adjustments when needed,” she says. Supportive care means treatments that ease side effects, such as anti-nausea medicine.
In the study, serious side effects were somewhat less common with Sone-Ve than with standard treatment: about 36% of people compared with about 45%. Serious stomach and gut problems were more common with Sone-Ve. Serious drops in blood counts were more common with standard treatment.
What We Still Don’t Know
Sone-Ve is still experimental and isn’t approved outside clinical trials.
It’s also unclear how well it works for people who already got zolbetuximab first. “We also need more experience with sonesitatug vedotin in patients previously treated with zolbetuximab, as relatively few patients in this study had received it,” Dr. Janjigian says.
A new study, CLARITY-Gastric02, is now testing Sone-Ve as a first treatment.
What This Means for You
If you have advanced stomach cancer, especially if you’ve been through several treatments, ask your doctor:
- Has my tumor been tested for claudin 18.2?
- Could I join a clinical trial of a claudin 18.2 drug?
- What’s my plan if my current treatment stops working?
“I think patients should be hopeful that we are continuing to develop more effective targeted therapies that can help them live longer, even when standard treatments have stopped working,” Dr. Janjigian says.
Learn more about SurvivorNet's rigorous medical review process.

